Karthik Selvaraju

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
The Acknowledgements section in this Article is incomplete: " We are grateful to Hans Rosén and Per Hagmar (Vivolux AB) for discussions and study support and to Marina Ciomei (Accelera, Nerviano, Italy) for performance of animal studies. We are grateful to Ingrid Holmberg for art-work. We acknowledge Cancerfonden, Radiumhemmets forskningsfonder,(More)
Inhibition of deubiquitinase (DUB) activity is a promising strategy for cancer therapy. VLX1570 is an inhibitor of proteasome DUB activity currently in clinical trials for relapsed multiple myeloma. Here we show that VLX1570 binds to and inhibits the activity of ubiquitin-specific protease-14 (USP14) in vitro, with comparatively weaker inhibitory activity(More)
  • 1